Skip to main content
SpringerLink
Log in

Endokrine Therapie des Mammakarzinoms

  • Chapter
Mammakarzinom

Part of the book series: Angewandte Onkologie ((AONKOLOGIE))

  • 35 Accesses

Zusammenfassung

Das normale Brustdrüsengewebe unterliegt einer Reihe von hormonellen Einflüssen. Die Beeinflußbarkeit kann auch nach maligner Transformation von Brustdrüsenzellen erhalten bleiben und macht somit endokrine Therapieformen beim Mammakarzinom möglich. Seit den ersten Beobachtungen von Beatson [1] und Schinzinger [2] vor fast 100 Jahren, daß die Ovarektomie eine Remission eines fortgeschrittenen Mammakarzinoms induzieren konnte, wurde eine Vielzahl von ablativen und additiven endokrinen Therapieformen versucht. Die Bedeutung dieser Therapieform muß immer wieder betont werden, da nicht nur Symptome gemildert werden, sondern auch zumindest bei postmenopausalen Patientinnen statistisch gesichert ist, daß das rezidivfreie und auch das Gesamt-Überleben verbessert werden können [3]. Außerdem sind endokrine Therapieformen nebenwirkungsarm und weniger toxisch als eine zytotoxische Chemotherapie. Die Entdeckung der Steroidhormonrezeptoren in den sechziger Jahren [4] und 1967 jener in Mammakarzinomzellen [5] haben wesentlich zum Verständnis der hormonellen Beeinflußbarkeit des Mammakarzinoms beigetragen, und der Steroidhormonrezeptormechanismus stellt den entscheidenden Ansatzpunkt der heutigen endokrinen Therapiemodalitäten dar.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet ii: 162

    Article  Google Scholar 

  2. Schinzinger K (1905) Das Karzinom der Mamma. Münch Med Wochenschr 2: 1724

    Google Scholar 

  3. Peto R (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28.896 women. N Engl J Med 319: 1681

    Google Scholar 

  4. Toft D, Gorski J (1966) A receptor molecule for estrogens: isolation from the rat utery and preliminary characterization. Proc Natl Acad Sci USA 55: 1574

    Article  PubMed  CAS  Google Scholar 

  5. Jensen EV, De Sombre ER, Jungblut PW (1967) Estrogen receptors in hormone-responsive tissues and tumors. In: Wissler RW (ed) Endogenous factors influencing host tumor balance. University of Chicago Press, Chicago, p 68

    Google Scholar 

  6. Molteni A, Bahu RM, Batifora HA, et al (1979) Estradiol receptor assays in normal and neoplastic tissues. A possible diagnostic aid for tumor differentiation. Ann Clin Lab Sci 9: 103

    PubMed  CAS  Google Scholar 

  7. Katzenellenbogen BS (1980) Dynamics of steroid hormone receptor action. Ann Rev Physiol 42: 17

    Article  CAS  Google Scholar 

  8. Butler WB, Kirkland WL, Gargola TL, et al (1983) Steroid stimulation of plasminogen activator production in a human breast cancer cell line (MCF-7). Cancer Res 43: 1637

    PubMed  CAS  Google Scholar 

  9. Eckert RL, Katzenellenbogen BS (1982) Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res 42: 139

    PubMed  CAS  Google Scholar 

  10. Lippman M, Bolan G, Huff K (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595

    PubMed  CAS  Google Scholar 

  11. Mange! WF, Toledo DL, Nardulli AM, et al (1988) Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. J Steroid Biochem 30: 79

    Article  Google Scholar 

  12. Sporn MB, Todaro G) (1980) Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878

    Article  PubMed  CAS  Google Scholar 

  13. Jakesz R, Smith CA, Aitken S, et al (1984) Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res 44: 619

    PubMed  CAS  Google Scholar 

  14. Lippman ME (1988) Steroid hormone receptors and mechanisms of growth regulation of human breast cancer. In: Lippman ME, Lichter AS, Danforth DN (eds) Diagnosis and management of breast cancer. Saunders, Philadelphia, p 326

    Google Scholar 

  15. Jakesz R, Kees A, Kolb R, et al (1982) Östrogen-and Progesteronrezeptoren beim primären Mammakarzinom. In: Jonat W, Maas H (Hrsg) Steroidhormonrezeptoren im Karzinomgewebe. Enke, Stuttgart, S 31

    Google Scholar 

  16. Reiner G, Jakesz R, Kolb R, et al (1988) Androgenrezeptoren beim primären Mammakarzinom: Beziehungen zu Prognosefaktoren im Vergleich mit Östrogen-and Progesteronrezeptoren. Dtsch Med Wochenschr 113: 892

    Article  PubMed  CAS  Google Scholar 

  17. Reiner A, Reiner G, Spona J, et al (1988) Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis. Cancer 61: 1149

    Article  PubMed  CAS  Google Scholar 

  18. Reiner A, Kolb R, Reiner G, et al (1987) Prognostic significance of steroid hormone receptors and histopathological characterization of human breast cancer. J Cancer Res Clin Oncol 113: 285

    Article  PubMed  CAS  Google Scholar 

  19. Kolb R, Reiner G, Jakesz R, et al (1979) Topische Unterschiede im Östrogenrezeptorgehalt primärer Mammakarzinome. In: Junghanns H (Hrsg) Chirurgisches Forum 1979 für experimentelle and klinische Forschung. Springer, Berlin Heidelberg New York, S 179

    Google Scholar 

  20. Jakesz R, Dittrich Ch, Hanusch J, et al (1985) Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy. Ann Surg 201: 305

    Article  PubMed  CAS  Google Scholar 

  21. Allegra JC, Barlock A, Huff KK, et al (1980) Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 45: 792

    Article  PubMed  CAS  Google Scholar 

  22. Mc Guire WL, Vollmer EP, Carbone PP (1975) Estrogen receptors in human breast cancer. Raven Press, New York

    Google Scholar 

  23. Reiner A, Neumeister B, Spona J, et al (1990) Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057

    PubMed  CAS  Google Scholar 

  24. Bryant AJS, Weir JA (1981) Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg Gynecol Obstet 153: 660

    PubMed  CAS  Google Scholar 

  25. Nissen-Meyer R (1967) The role of prophylactic castration in the therapy of human mammary cancer. Eur J Cancer 3: 395

    PubMed  CAS  Google Scholar 

  26. Cole MP (1968) Suppression of ovarian function in primary breast cancer. In: Forrest APM, Kunkler PB (eds) Prognostic factors in breast cancer. Livingston, Edinburgh, p 146

    Google Scholar 

  27. Meakin JW (1986) Review of Canadian trials of adjuvant endocrine therapy of breast cancer. NCI Monographs 1: 111

    PubMed  Google Scholar 

  28. Kaufmann M (persönliche Mitteilung)

    Google Scholar 

  29. Nolvadex Adjuvant Trial Organization (1985) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet i: 836

    Google Scholar 

  30. Goldhirsch A, Gelber R (1986) Adjuvant treatment for early breast cancer. The Ludwig Breast Cancer Studies. NCI Monographs 1: 55

    PubMed  Google Scholar 

  31. Mouridson HT, Andersen AP, Brinker H, et al (1986) Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients. Present status of the Danish breast cancer cooperative group trials. NCI Monographs 1: 115

    Google Scholar 

  32. Cummings FJ, Gray R, Davis TE, et al (1986) Tamoxifen vs placebo: double blind adjuvant trial in elderly women with stage II breast cancer. NCI Monographs 1: 119

    PubMed  Google Scholar 

  33. Tormey DC, Gray R, Taylor SG, et al (1986) Postoperative chemotherapy and chemohormonal therapy in women with nodal positive breast cancer. NCI Monographs 1: 75

    PubMed  Google Scholar 

  34. Kaufmann M, Maass H, Kubli F, et al (1984) Risk adapted adjuvant chemohormone therapy in operable nodal positive breast cancer. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer IV. Grune Stratton, Orlando, p 369

    Google Scholar 

  35. Pannuti F, Martoni A, Di Marco AR, et al (1979) Prospective randomized clinical trial of two different high dosages of medroxy-progesterone acetate ( MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15: 593

    PubMed  CAS  Google Scholar 

  36. McIntosh IH, Thynne GS (1977) Tumor stimulation by antiestrogens. Br J Surg 64: 900

    Article  PubMed  CAS  Google Scholar 

  37. Jordan VC (1984) Bischemical pharmacology of antiestrogen action. Pharmacol Rev 36: 245

    PubMed  CAS  Google Scholar 

  38. Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127

    Article  PubMed  CAS  Google Scholar 

  39. Patterson JS, Battersby LA, Edwards DG (1982) Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. Rev Endocr Rel Cancer [Suppl 9]: 563

    Google Scholar 

  40. Pritchard KI, Thomson DB, Myers RE, et al (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787

    PubMed  CAS  Google Scholar 

  41. Santen RS, Lipton A, Kendall J (1974) Successful medical adrenalectomy with aminoglutethimide. Role of altered drug metabolism. JAMA 230: 1661

    Article  PubMed  CAS  Google Scholar 

  42. Santen RJ, Worgul TJ, Samojlik E, et al (1981) Randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545

    Article  PubMed  CAS  Google Scholar 

  43. Coombes RC, Goss P, Dowsett M, et al (1984) 4-Hydroxyandrostendione in treatment of postmenopausal patients with advanced breast cancer. Lancet i:1237

    Google Scholar 

  44. Kaufmann M, Jonat W, Kleeberg V, et al (1989) Goserelin, a depot gonadotropinereleasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J CI in Oncol 7: 1113

    CAS  Google Scholar 

Download references

Authors
  1. G. Reiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag/Wien

About this chapter

Cite this chapter

Reiner, G. (1992). Endokrine Therapie des Mammakarzinoms. In: Mammakarzinom. Angewandte Onkologie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7615-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-7615-3_7

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82313-2

  • Online ISBN: 978-3-7091-7615-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation